CD8A and melanoma: When challenged with B16 melanoma or LCMV-Clone 13, mice given Fgl2-deficient antigen-specific CD8+ T cells exhibited enhanced antitumor and antiviral response via increased persistence of antigen-specific CD8+ T cells.